Halozyme CEO reports 10b5-1 option exercises and share sales

Rhea-AI Filing Summary

Halozyme Therapeutics (HALO) insider activity: The President and CEO, who also serves as a director, exercised stock options and sold shares under a Rule 10b5-1 trading plan adopted on March 21, 2025.

Across November 10–12, 2025, the executive exercised 60,000 options at $8.11 per share (20,000 each day) and sold 60,000 shares in multiple tranches. Reported weighted average sales prices included $68.714 and $69.3 on November 10; $67.892, $68.795, and $69.731 on November 11; and $70.218, $71.089, and $71.667 on November 12. The sales reflect shares acquired from option exercises, with the underlying options having a ten‑year term expiring in February 2026.

Following the reported transactions, the executive beneficially owned 733,719 shares directly. Remaining options beneficially owned declined to 16,569 after these exercises.

Insider Trade Summary

Net Seller: 60,000 shares ($4,167,930)

Net Sell 14 txns

Insider Torley Helen

Role PRESIDENT AND CEO

Sold 60,000 shs ($4.17M)

Type	Security	Shares	Price	Value
Exercise	Option to Purchase Common Stock	20,000	$8.11	$162K
Exercise	Common Stock	20,000	$8.11	$162K
Sale	Common Stock	12,718	$70.218	$893K
Sale	Common Stock	6,784	$71.089	$482K
Sale	Common Stock	498	$71.667	$36K
Exercise	Option to Purchase Common Stock	20,000	$8.11	$162K
Exercise	Common Stock	20,000	$8.11	$162K
Sale	Common Stock	4,500	$67.892	$306K
Sale	Common Stock	4,000	$68.795	$275K
Sale	Common Stock	11,500	$69.731	$802K
Exercise	Option to Purchase Common Stock	20,000	$8.11	$162K
Exercise	Common Stock	20,000	$8.11	$162K
Sale	Common Stock	19,900	$68.714	$1.37M
Sale	Common Stock	100	$69.30	$7K

Holdings After Transaction: Option to Purchase Common Stock — 16,569 shares (Direct); Common Stock — 753,719 shares (Direct)

Footnotes (1)

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.250 to $69.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.395 to $68.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.400 to $69.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.400 to $69.940. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.570 to $70.565. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.570 to $71.560. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.575 to $71.730. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		M(1)		20,000	A	$8.11	753,719	D
Common Stock	11/10/2025		S(1)		19,900	D	$68.714(2)	733,819	D
Common Stock	11/10/2025		S(1)		100	D	$69.3	733,719	D
Common Stock	11/11/2025		M(1)		20,000	A	$8.11	753,719	D
Common Stock	11/11/2025		S(1)		4,500	D	$67.892(3)	749,219	D
Common Stock	11/11/2025		S(1)		4,000	D	$68.795(4)	745,219	D
Common Stock	11/11/2025		S(1)		11,500	D	$69.731(5)	733,719	D
Common Stock	11/12/2025		M(1)		20,000	A	$8.11	753,719	D
Common Stock	11/12/2025		S(1)		12,718	D	$70.218(6)	741,001	D
Common Stock	11/12/2025		S(1)		6,784	D	$71.089(7)	734,217	D
Common Stock	11/12/2025		S(1)		498	D	$71.667(8)	733,719	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$8.11	11/10/2025		M(1)			20,000	(9)	02/03/2026	Common Stock	20,000	$8.11	56,569	D
Option to Purchase Common Stock	$8.11	11/11/2025		M(1)			20,000	(9)	02/03/2026	Common Stock	20,000	$8.11	36,569	D
Option to Purchase Common Stock	$8.11	11/12/2025		M(1)			20,000	(9)	02/03/2026	Common Stock	20,000	$8.11	16,569	D

Explanation of Responses:

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.250 to $69.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.395 to $68.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.400 to $69.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.400 to $69.940. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.570 to $70.565. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.570 to $71.560. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.575 to $71.730. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

9. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HALO’s CEO report in this Form 4?

Option exercises and related sales under a Rule 10b5-1 plan over November 10–12, 2025.

How many options were exercised and at what price?

A total of 60,000 options were exercised at $8.11 per share (20,000 each day).

How many shares were sold and at what prices?

A total of 60,000 shares were sold in tranches at weighted average prices including $68.714, $69.3, $67.892, $68.795, $69.731, $70.218, $71.089, and $71.667.

Were these transactions under a 10b5-1 plan?

Yes. The plan was adopted on March 21, 2025 in accordance with Rule 10b5-1.

What are the executive’s holdings after the transactions?

Direct beneficial ownership is 733,719 shares after the reported transactions.

What options remain after the exercises?

The executive beneficially owns 16,569 options after the transactions, with the grant dated February 3, 2016 and expiring in February 2026.

What were the price ranges for the weighted averages disclosed?

Ranges disclosed include $67.395–$68.360, $68.400–$69.350, $69.400–$69.940, $69.570–$70.565, $70.570–$71.560, and $71.575–$71.730.